Complete Regression of Lung Metastases in a Patient With Metastatic Castration-Resistant Prostate Cancer Using 177Lu-PSMA Radioligand Therapy

Clin Nucl Med. 2020 Jan;45(1):e48-e50. doi: 10.1097/RLU.0000000000002655.

Abstract

Patients with metastatic castration-resistant prostate cancer (mCRPC) and visceral (liver or lung) metastases have a poor prognosis and worse outcomes than those with bone disease with or without lymph nodes involvement. The high prostate-specific membrane antigen expression in prostate cancer metastases makes it a promising approach for targeted radionuclide therapy of prostate cancer. Lutetium-177 (Lu)-labeled prostate-specific membrane antigen radioligand therapy (Lu-PRLT) has demonstrated encouraging efficacy in mCRPC. We report here an mCRPC patient with lung, lymph nodes, and extensive bone metastases, who underwent Lu-PRLT and had excellent response to the treatment and complete regression of lung metastases after Lu-PRLT.

Publication types

  • Case Reports

MeSH terms

  • Dipeptides / therapeutic use*
  • Heterocyclic Compounds, 1-Ring / therapeutic use*
  • Humans
  • Lung Neoplasms / radiotherapy*
  • Lung Neoplasms / secondary*
  • Lutetium
  • Lymphatic Metastasis
  • Male
  • Middle Aged
  • Prostate-Specific Antigen
  • Prostatic Neoplasms, Castration-Resistant / pathology*
  • Treatment Outcome

Substances

  • 177Lu-PSMA-617
  • Dipeptides
  • Heterocyclic Compounds, 1-Ring
  • Lutetium
  • Prostate-Specific Antigen